
Macromed Inc Profile last edited on: 7/24/08
CAGE: 4C8K3
UEI:
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2417 South 3850 West
West Valley City, UT 84120
West Valley City, UT 84120
(801) 582-2131 |
macromed@macromed.com |
www.macromed.com |
Location: Single
Congr. District: 02
County: Salt Lake
Congr. District: 02
County: Salt Lake
Public Profile
In December 2006, MacroMed, Inc., a private drug development and manufacturing company, signed an agreement to be acquired by the UK-based biopharmaceutical company, Protherics PLC, pursuant to an agreement and plan of merger and reorganization. The merger is an all-stock acquisition of MacroMed and its lead product, OncoGel(R), a novel sustained-release formulation of paclitaxel being developed for local administration in the treatment of esophageal and brain cancer. MacroMed was founded by the world-renown University of Utah professor, Dr. Sung Wan Kim. The focus of the company is to create new formulations of existing drugs using its novel polymeric technologies. MacroMed's technology platform includes ReGel(R), a temperature-sensitive, bioerodible hydrogel, HySolv(TM), a drug solubilizer, and SQZGel(TM), an oral sustained-release technology. The company's lead product, OncoGel, is currently completing a phase 2a clinical study for the palliation of esophageal cancer and is expected to enter clinical trials in 2007 for the local treatment of brain cancer.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2006 | 1 | NIH | $100,000 | |
Project Title: IL-2/ReGel as immunotherapy of solid tumors |
Key People / Management
Kirk D Fowers
James Herrin
James Herrin
Company News
There are no news available.